For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Mettler-Toledo International Inc. (MTD) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-09-21): Designation Watch · Gem Score -13 (−100…+100 Quality+Value blend) · Quality 76 · Value -73 · Sentiment -9 (timing only, not weighted) · Composite fair value $661.70 vs $1,398.22 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Mettler-Toledo International Inc.
MTD NYSEMettler-Toledo International Inc. is a global precision instruments company that provides weighing, analytical, and inspection solutions for laboratory, industrial, and food retail customers. Its product portfolio includes laboratory balances, pipettes, pH meters, process analytics instruments, metal detection systems, and end-of-line inspection equipment used in research, quality control, production, logistics, and retail operations. The company serves industries such as life sciences, pharmaceuticals, biotechnology, chemicals, manufacturing, and food processing, where measurement accuracy and process reliability are essential. Mettler-Toledo International Inc. also supports customers with related services and a worldwide sales and service network, making it an important supplier of mission-critical measurement technologies across multiple regulated and production-intensive markets.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 42.05
Total Equity: -$23.64M
Shares: 20,671,708
Total Debt: $2.17B
Cash: $66.89M
EBITDA: $1.24B
Total Debt: $2.17B
Cash: $66.89M
Revenue: $4.03B
Revenue: $4.03B
Revenue: $4.03B
Total Equity: -$23.64M
Tax Rate: 17.1%
Equity: -$23.64M
Total Debt: $2.17B
Cash: $66.89M
Current Liabilities: $1.20B
Long-Term Debt: $2.10B
Total Debt: $2.17B
Total Equity: -$23.64M
Shares: 20,671,708
Shares: 20,671,708
CapEx: -$107.12M
Shares: 20,671,708
Stock Price: $1,398
Net Income: $869.19M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 29, 2026 5:13am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.7B | $3.9B | $3.8B | $3.9B | $4.0B |
| Cost of Revenue | $1.5B | $1.6B | $1.5B | $1.5B | $1.6B |
| Gross Profit | $2.2B | $2.3B | $2.2B | $2.3B | $2.4B |
| Operating Expenses | $1.1B | $1.1B | $1.1B | $1.1B | $1.2B |
| Operating Income | $1.1B | $1.2B | $1.2B | $1.2B | $1.2B |
| Net Income | $769.0M | $872.5M | $788.8M | $863.1M | $869.2M |
| EBITDA | $1.1B | $1.2B | $1.2B | $1.3B | $1.2B |
| EPS | $33.25 | $38.79 | $36.10 | $40.67 | $42.17 |
| EPS (Diluted) | $32.78 | $38.41 | $35.90 | $40.48 | $42.05 |
Balance Sheet (Annual)
Last updated: Aug 29, 2026 5:00am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $98.6M | $96.0M | $69.8M | $59.4M | $66.9M |
| Total Current Assets | $1.3B | $1.4B | $1.2B | $1.2B | $1.4B |
| Total Assets | $3.3B | $3.5B | $3.4B | $3.2B | $3.7B |
| Current Liabilities | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B |
| Long-Term Debt | $1.6B | $1.9B | $1.9B | $1.8B | $2.1B |
| Total Liabilities | $3.2B | $3.5B | $3.5B | $3.4B | $3.7B |
| Total Equity | $171.4M | $24.8M | -$149.9M | -$126.9M | -$23.6M |
| Retained Earnings | $5.9B | $6.7B | $7.5B | $8.4B | $9.2B |
Cash Flow (Annual)
Last updated: Aug 29, 2026 5:25am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $908.8M | $859.1M | $965.9M | $968.3M | $955.8M |
| Capital Expenditure | -$107.6M | -$121.2M | -$105.3M | -$103.9M | -$107.1M |
| Free Cash Flow | $801.2M | $737.8M | $860.6M | $864.4M | $848.6M |
| Acquisitions (net) | -$220.9M | -$38.0M | -$5.8M | -$10.1M | -$93.8M |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$1,000.0M | -$1.1B | -$900.0M | -$850.0M | -$800.0M |
| Net Change in Cash | $4.3M | -$2.6M | -$26.2M | -$10.4M | $7.5M |
Growth Trends (YoY %)
Last updated: Aug 29, 2026 5:13am (23d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +5.4% | -3.4% | +2.2% | +4.0% |
| Gross Profit Growth | +6.3% | -2.9% | +3.8% | +2.8% |
| Operating Income Growth | +12.7% | -3.4% | +4.2% | -0.6% |
| Net Income Growth | +13.5% | -9.6% | +9.4% | +0.7% |
| EBITDA Growth | +12.4% | -3.1% | +4.1% | -0.5% |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-09-20 02:03A +1σ run of quarters pays -68%; a −1σ run costs 77%. Ratio -0.9:1 (μ 4.3%, σ 5.1% , 16 pairs).
Older method (repeat-worst-quarter): -0.9 : 1
| Case | Growth | Margin | Fair value | vs price ($1,398.22) |
|---|---|---|---|---|
| Bull — recovery | +7% | 25.2% | $462.60 | -67% |
| Base — stabilizes | +4% | 21.9% | $382.65 | -73% |
| Bear — keeps slipping | +2% | 18.6% | $311.44 | -78% |
| Stress — last quarter repeats | +4% | 21.9% | $384.22 | -73% |
| Upside — a +1σ run of quarters (v2) | +9% | 21.9% | $448.35 | -68% |
| Stress — a −1σ run of quarters (v2) | -1% | 21.9% | $324.64 | -77% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-29 05:35The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw numbers first: MTD is doing $4.03B TTM revenue growing ~4% YoY, with operating margins parked at 29-30% and net margins around 22%. The five-year revenue CAGR is 3.1% and earnings CAGR 5% — this is a GDP-plus business, full stop. FCF actually declined from ~$860M in 2021 to $848M in 2025, so the "compounder" narrative is running on multiple expansion and buybacks, not organic cash generation. The balance sheet tells the story: $2.17B debt against $67M cash and *negative* $23.6M equity. That's not a fortress — that's a company that has bought back so much stock it's mathematically levered its equity to zero. ROA of 23% looks great until you realize the denominator is small because the buybacks have shredded the asset base.
Now the quarterly trajectory is where I disagree slightly with the "decelerating" framing. Q2 2026 revenue of $1.03B is +4.7% YoY vs Q2 2025's $983M, and Q2 net income of $233M is +15% YoY on margin expansion to 22.7% from 20.6%. Q1 2026 was softer ($947M vs $884M, +7.2%) but Q1 is seasonally the smallest quarter. So there's actually a modest re-acceleration in earnings via margin lift, not revenue. That said, it's not enough to justify a 33x P/E on a business compounding EPS at ~5-7%. The synthesis DCF at $683-710 implies an ~18-20x multiple which is defensible for this growth profile; the current 33x prices in either a biopharma capex boom or margin expansion to 25%+ net that I don't see supported in the sequential numbers.
Where I'd push back on the prior models: the synthesis "-49% overvalued" verdict is directionally right but probably too aggressive on magnitude. A quality-adjusted multiple for a mid-single-digit grower with 30% operating margins and $850M in FCF should land at ~25x earnings or roughly $1,050-1,100, not $710. The DCF is likely using a terminal growth that's too punitive for a business with genuine switching costs and regulatory embedding. The market-forces "neutral" call underweights the debt/negative-equity issue — a 4% revenue growth business with $2.17B debt and declining FCF has real vulnerability if pharma/biotech capex stays soft into 2027. The insider activity is genuinely neutral — these are small option-exercise-and-sell mechanics, not signal. The narrative model correctly identifies the "quality tax" but I'd argue the tax has expanded well past what fundamentals can carry; every point of multiple compression from 33x to 25x is a 24% drawdown.
A careful contrarian would argue three things: first, MTD has consistently earned its premium — this is the same "overvalued on DCF" argument that's been wrong for a decade because the market correctly identifies scarce compounders; second, margin expansion from 20.6% to 22.7% in one year is real operating leverage that DCFs miss; third, pharma capex is cyclical and coming off a trough, so the "decelerating" read may be exactly wrong timing. I take these seriously but note that even generous assumptions — 6% revenue growth, 24% net margins, 25x exit multiple — get you to ~$1,150, still below current. The margin of safety is negative. My read: overvalued, but fair value is closer to $1,000-1,100 than $710. I partially agree with the synthesis direction, dissent on magnitude. This isn't a short (quality businesses grind higher on multiple stickiness), but it's not a buy anywhere near $1,400. Wait for a biotech capex disappointment or a broader multiple compression event to get in at $1,050 or below.
GPT Reading
Mettler-Toledo looks exactly like the kind of business investors should pay up for, but not this much. The operating model is superb: on 2025 revenue of $4.03B it produced $1.19B of operating income, an exceptional 29.6% operating margin, and $848.6M of free cash flow, or roughly 21% FCF margin. Gross margin near 59% says this is not a commodity instrument vendor, and the quarterly cadence shows resilient profitability even through uneven demand: net margin ran 18%-25% across the last eight quarters, with June 2026 at 22.7% on $1.03B of revenue. That quality is real. The problem is that the growth profile underneath the premium is not. Revenue is only modestly above 2022’s $3.92B despite three more years passing, and 2025 net income of $869.2M is basically flat with 2022’s $872.5M. Even the recent recovery is solid rather than explosive: June 2026 revenue of $1.03B was up about 4.8% from $983.2M a year earlier, while net income rose 15%, but March 2026 net income of $169.5M was only 3.6% above the prior year quarter. For a stock at $1,398 trading at 33x earnings and nearly 25x EV/EBITDA, that is not enough.
What stands out most is the mismatch between durability and acceleration. This is a wonderful “steady compounder” financial profile being valued like a higher-growth platform asset. On trailing numbers, the market cap of $28.2B against annual sales of $4.03B implies over 7x sales for a company growing low single digits over a multiyear period. Free cash flow yield is only about 3.0% on market cap ($848.6M / $28.2B), which would be easier to defend if FCF were compounding at double digits, but the supplied figures show FCF CAGR slightly negative. The balance sheet also matters more than bulls admit: cash is just $66.9M against $2.17B of debt, and equity is negative. Negative equity is not inherently alarming in a buyback-heavy compounder, but it does tell you the financial engineering has been aggressive enough that future returns need operating performance to stay very clean. At this valuation, a business that merely remains excellent but mature can still be a bad stock.
The best argument against my read is straightforward: Mettler-Toledo has earned its premium for years because its end markets reward precision, compliance, service quality, and uptime, not lowest price. A company with 59% gross margins, 30% operating margins, and 89% FCF conversion of net income ($848.6M versus $869.2M) is not easy to replicate. The quarterly data also suggest the business may be reaccelerating after a soft patch: revenue went from $883.7M in March 2025 to $947.1M in March 2026, and from $983.2M in June 2025 to $1.03B in June 2026, while June-quarter net margin improved from 20.6% to 22.7%. If this is the beginning of a cleaner post-biotech-slump rebound, then today’s multiple may prove less excessive than it looks on backward averages. And because the business is so asset-light, even modest growth can drive outsized per-share earnings if buybacks continue.
I still weigh those positives differently because the stock already discounts that favorable scenario. You do not need to prove Mettler is high quality; the market has priced that in abundantly. What is not priced with enough skepticism is the possibility that this remains a mid-single-digit grower with limited room for further margin expansion. Operating income in 2025 was actually slightly below 2024 ($1.19B versus $1.20B) despite higher revenue, so the idea of a smooth margin staircase upward is not in the data. Likewise, annual revenue growth from 2024 to 2025 was only about 4.1%, and from 2021 to 2025 it was roughly 2.0% CAGR on the raw annual figures. That can justify a premium industrial-healthcare multiple, but not one that leaves essentially no room for cyclical disappointment. The insider prints shown are mostly option exercises paired with sales, so they are not a major signal, but they certainly do not offset valuation risk.
What would change my mind is not another quarter of 4%-5% growth with stable margins; that simply validates the current business quality. I would want to see evidence that Mettler can sustainably grow faster than its recent history while preserving its margin structure — for example, annual revenue moving convincingly above a $4.3B-$4.4B run rate with quarterly net margins still above 22%, or free cash flow breaking through $1.0B without leverage rising further. If instead the next few quarters show revenue slipping back below $1.0B or net income stalling near the current run rate, the multiple will look even harder to defend. My base case is that this is a great company priced as an even better one.
Grok Reading
The numbers on Mettler-Toledo describe a superb franchise that has stopped compounding at a rate that justifies its price. Annual revenue crawled from $3.72B in 2021 to $4.03B in 2025—a 3.1% CAGR—while 2025 net income of $869M sits essentially flat versus 2022’s $872M. Recent quarters show the same pattern: $1.03B revenue in the June 2026 quarter is only modestly above the year-ago $983M, and trailing earnings growth has compressed to 0.7% YoY. Against that, the market still awards a 33× P/E, 7.2× sales and nearly 25× EV/EBITDA. The valuation synthesis putting intrinsic value near $710 (signal-adjusted) versus $1,398 spot is directionally correct; the stock embeds a perpetual high-single-digit growth and margin-expansion story the income statement simply does not deliver.
What the business does deliver is exceptional quality. Gross margin holds at 59%, operating margin near 30%, net margin 22%, and free-cash-flow conversion is elite—$849M FCF on $956M operating cash flow after only $107M of capex. ROA above 23% confirms the installed-base and service economics are real. The problem is capital allocation and leverage: $2.17B of debt against $67M of cash and *negative* equity of –$24M shows years of aggressive buybacks have hollowed the balance sheet. That financial engineering props up per-share metrics while FCF itself has a –0.7% CAGR. Insiders exercising and immediately selling small option lots add no bullish signal. The “mature earner” archetype is accurate; the platform-monopoly narrative the market is paying for is not supported by 4% recent revenue growth or decelerating quarterly trends.
The strongest counter-argument is that mission-critical measurement in regulated pharma, biotech and food safety truly does carry pricing power and switching costs that deserve a scarcity premium, and that 33× on a 22% net-margin business with 85%+ FCF conversion is how the market has long paid for MTD’s reliability through cycles. A smart opponent would also note that 2025 operating income of $1.19B is still robust, that gross profit dollars keep rising, and that any reacceleration in biotech capex or lab instrument mix could restore mid-single-digit organic growth and make the multiple look less stretched in hindsight. I weigh that less heavily because the same “essential infrastructure” story has been priced for years while reported growth has decelerated, FCF has stagnated, and the balance sheet has been loaded with buyback debt—leaving little cushion if the cyclical pharma/biotech headwinds persist. Quality without growth at twice modeled fair value is still expensive.
I would reverse to a more constructive stance if organic revenue growth sustains above 7–8% for two consecutive quarters, if operating margin pushes through 31–32% on mix, or if FCF re-accelerates above $1B while net debt is reduced rather than re-levered for buybacks. Until those prints appear, the gap between $1,398 and fundamentals-dominated value near $700–750 remains the dominant fact.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Mettler-Toledo posts the financial signature of a top-tier industrial franchise: gross margin expanded from 58.4% (2021) to 59.4% (2025) with a 60.1% peak, operating margin held at 29-31%, and net income grew from $769M to $869M on revenue rising $3.72B to $4.03B. FCF ran $737M-$864M across five years, converting at roughly 100% of net income (OCF/NI 1.12x, accruals -2.9% of assets), and Altman Z of 10.21 with Beneish M of -2.44 indicate no mechanical earnings-quality flags. Diluted share count fell from 23.5M to 20.7M (-3.1% CAGR) with buybacks running 4,665% of SBC and SBC only 0.6% of revenue - a genuine capital-return machine, not optics. The one qualifier is the balance sheet: liquid cash is just $66.9M against $2.10B net debt, so the 'fortress' descriptor applies to the earnings/cash engine, not the cash cushion. Given ~$848M annual FCF, debt is easily serviceable and clearly a deliberate capital-structure choice (leverage the buyback), not distress - but it does mean there is no war chest and any severe demand shock would tighten the screws. Insider tape shows only routine option-exercise-and-sell activity ($4.75M in sales, no open-market buys); neutral, not a red flag at this scale. Revenue growth is modest (~2% CAGR over five years) - this is a mature compounder, not a grower - but margin durability and per-share compounding through buybacks are what carry the quality grade.
Verify before trusting this (5)
- Debt maturity ladder and covenants on the $2.1B net debt position
- Segment/geographic mix and any customer or China exposure driving the 2023 revenue dip
- Whether 2025 margin compression is FX, mix, or pricing-driven per management commentary
- Organic vs FX/M&A contribution to the 2025 revenue reacceleration
- Pension and lease obligations not captured in headline net debt
The composite fair value lands at $683 and the signal-adjusted FV at $710, implying the market price of $1,398 embeds roughly 49% downside to deserved value. The DCF ($516) and EPV floor ($318) both scream expensive, and even the anchored-PE method - which just extrapolates the current multiple - only gets to $1,381, essentially the current price. In other words, the ONLY way today's price makes sense is if MTD keeps trading at its historical premium multiple forever; on cash-flow fundamentals it is priced for perfection. Earnings quality is high (score 3), so there is no haircut to apply - the gap is real, not an accounting mirage. Company quality is Fortress-grade (60% gross margins, ~$850M FCF, steady buybacks), which absolutely raises deserved value versus a generic industrial - but Fortress quality is already the consensus view here and is fully in the price. What has to go right to justify $1,398? Sustained mid-single-digit organic growth, continued margin expansion off already ~30% operating margins, and no multiple compression from ~30x earnings. That is a heroic stack for a mature instrumentation franchise growing single digits. Verdict: fairly-to-richly priced quality compounder, not a mispricing.
Verify before trusting this (4)
- Organic constant-currency growth trajectory in next 2-3 quarters vs mid-single-digit assumption
- Operating margin ceiling - is 30%+ sustainable or peaking
- Pace and price of buybacks at current multiple
- China and pharma end-market recovery cadence in guidance
The macro tape is mildly supportive: VIX at 14.4, S&P near highs, risk-on regime building. With a 1.22 beta MTD would normally amplify tape moves, but this is a defensive diagnostics/measurement name whose price action is driven more by rate sensitivity and narrative than by daily risk appetite. The 10y at 4.67% and a market PE of 26 are a subtle drag on any long-duration quality compounder trading at a premium multiple - and MTD is the archetype of that cohort. Narrative-wise, the platform-monopoly story is intact but only moderate in intensity and durability, with low cult coefficient - meaning there is no fervent buyer base defending the stock, but also no active de-rating catalyst. The recent Barchart piece frames MTD as an underperformer over the past year with cautiously optimistic analyst tone; that is a lukewarm setup - not a squeeze, not a rout. Applied to this name specifically: MTD has quietly lagged, the story has gone stale rather than broken, and there is no fresh news flow either way. Pressure is a low-magnitude headwind from valuation-narrative fatigue and rates, offset by a benign tape and constructive sell-side.
Verify before trusting this (4)
- Any analyst target revisions or downgrades that would crack the cautiously-optimistic consensus
- Rotation flows in life-sciences tools (A, DHR, TMO) - a cohort-level de-rating would drag MTD
- Rate moves - a break above 4.75% on the 10y presses premium-multiple compounders harder
- Whether the platform-monopoly narrative gets a fresh catalyst (biopharma capex cycle turn) or fades further
The world MTD sells into is one of tightening measurement and traceability requirements — GMP pharma, food-safety inspection, battery and semiconductor process control — which keeps its products non-optional and repriceable. But the same world is capital-disciplined: pharma is cutting SG&A and R&D overheads, public research funding is under pressure, and 4.67% long rates with macro headwinds keep industrial capex committees conservative. Net effect: demand is durable and slowly growing, not inflecting. AI and lab automation are mildly positive for MTD (more instruments feeding data systems, more automated pipetting and inline analytics) but do not change the unit economics or the growth rate. The honest read is a high-quality, GDP-plus-price compounder in a world that offers it no accelerant.
When we made this prediction on Aug 29, 2026, MTD was $1,398.22. We expect it to be $1,275.00 by Mar 2027, and we consider it great value under $950.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 29, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
trailing_eps
flips up 10%
adjusted_pe
flips up 10%